Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020.

ABSTRACT:

Background

While Latin America has been heavily affected by the pandemic, only a few seroprevalence studies have been conducted there during the first epidemic wave in the first half of 2020.

Methodology/principal findings

A cross-sectional survey was performed between 15 July 2020 and 23 July 2020 among individuals who visited 4 medical laboratories or 5 health centers for routine screening or clinical management, with the exception of symptomatic suggestive cases of covid-19. Samples were screened for the presence of anti-SARS-CoV-2 IgG directed against domain S1 of the SARS-CoV-2 spike protein using the anti-SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) from Euroimmun.

Conclusions/significance

The overall seroprevalence was 15.4% [9.3%-24.4%] among 480 parti

SUBMITTER: Flamand C 

PROVIDER: S-EPMC8639096 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature